Malignant Genito-urinary Tumors in Children: South Egypt Cancer Institute Experience
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Genitourinary Neoplasms
- Sponsor
- Assiut University
- Enrollment
- 250
- Locations
- 1
- Primary Endpoint
- Event Free Survival (EFS)
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
The aim of this study is to identify demographic & disease characteristics in pediatric oncology patients diagnosed with one of genitourinary tumors & treatment outcomes in these patients.
Detailed Description
Background: Tumors of the kidney, bladder, prostate, testis, and adrenal represent a large part of the adult urologic practice, but are relatively infrequent in children. Genitourinary tumors contribute to pediatric solid tumors. Wilms tumor, rhabdomyosarcoma, and germ cell tumors are the most common malignant genitourinary tumors in children. The natural history and management of these tumors in the pediatric age is different from that of the adults. As result of the successful work of several clinical trial groups in recent decades, there has been a significant improvement in their cure rates. Patients \& Methods: From January 2001 till December 2015, retrieval \& analysis of the medical records of pediatric patients with genitourinary tumors will be made at the pediatric oncology department, South Egypt Cancer Institute which represents the largest referral center in Upper Egypt. These data will be categorized according to demographic characteristics, clinico-pathologic features, treatment modalities received, and outcomes of treatments in these patients.
Investigators
Ahmed Mohammed Morsy, MD
Lecturer, Pediatric Oncology Department
Assiut University
Eligibility Criteria
Inclusion Criteria
- •Patients whose age less than or equal to 18 years.
- •Patients diagnosed with any of neoplasms affecting the genitourinary system.
Exclusion Criteria
- •Patients whose age more than 18 years.
Outcomes
Primary Outcomes
Event Free Survival (EFS)
Time Frame: Participants will be retrospectively followed forward in time from the date of initiation of treatment till the primary completion date of the study, an expected average of 5 years
Time from the date of initiation of treatment until disease progression, or death for any reason.
Overall survival (OS)
Time Frame: Participants will be retrospectively followed forward in time from the date of initiation of treatment till the primary completion date of the study, an expected average of 5 years
Time from the date of initiation of treatment until death from any cause